Gerresheimer's Fate Hangs on a Delayed Audit and Legal Reckoning

German pharma packager Gerresheimer faces a perfect storm: a €35M accounting scandal triggers loan defaults, creditor talks, asset sales, and legal threats, with its stock down 68%.

The clock is ticking for German pharmaceutical packaging supplier Gerresheimer. With its stock down roughly 68% year-on-year and trading near €17.44, the company is navigating a perfect storm of accounting scandals, creditor negotiations, and legal threats, all while operating in a critical information vacuum. The next decisive milestone is not until June 2026, when a long-overdue audited annual report is finally expected.

At the heart of the crisis are systematic violations of IFRS accounting rules related to so-called "bill-and-hold" transactions. An independent law firm confirmed the company prematurely booked revenue for goods that were invoiced but not yet shipped. The scale is significant: €35 million in misbooked revenue for 2024, requiring a €24 million correction to adjusted EBITDA, and planned impairment charges totaling between €220 million and €240 million. The German financial regulator, BaFin, has expanded its probe beyond these revenue bookings to also examine leasing liabilities and risks associated with the Bormioli Pharma acquisition.

This accounting debacle has triggered a chain reaction with severe consequences. The absence of a certified financial statement for fiscal 2024/25 means Gerresheimer is in technical default on its loan covenants, breaching contractual reporting obligations. Management is currently locked in talks with lenders to secure waivers and extend deadlines, aiming to prevent a termination of its credit facilities. Failure to present the audited 2025 report by June would severely narrow its negotiating room.

The situation has also drawn the ire of shareholder activists. The Deutsche Schutzvereinigung für Wertpapierbesitz (DSW) is examining concrete claims for damages against former members of Gerresheimer's management board. The association is investigating whether the accounting irregularities constitute breaches of duty that could lead to personal liability for the ex-executives.

Operationally, the company is scrambling to create financial breathing room. It has mandated Morgan Stanley to sell its US subsidiary Centor, which was valued at €292 million at the end of 2024. Furthermore, Gerresheimer is closing its moulded-glass plant in Chicago by the end of 2026, shifting production to Italy and India. This move, while expected to stabilize margins long-term, contributes to the current wave of non-cash impairments.

The stock's decline has been exacerbated by its expulsion from the SDAX index on April 10, after it failed to submit its audited accounts on time. Its replacement by the Shelly Group forced index-tracking ETFs to divest their holdings, creating structural selling pressure. The share price, now approximately 73% below its 52-week high of €64.40, shows a Relative Strength Index (RSI) of 25.6, indicating a technically oversold condition.

Despite the overwhelming negativity, some institutional investors see an entry point. Firms like CastleKnight and Deka Investment have recently reported new stakes in the company. For them and all other stakeholders, however, the path forward remains opaque. Key events like the Q1 2026 report and the Annual General Meeting, originally scheduled for June, remain postponed. The next scheduled financial updates are the half-year report on July 14 and the Q3 statement on October 15.

The role of auditor KPMG adds another layer of complexity. Having replaced Deloitte in 2024, KPMG subsequently issued an unqualified audit opinion on the flawed financial statements. Germany's audit oversight body, APAS, has now initiated professional disciplinary proceedings against the firm. Everything now converges on June 2026. The audited annual statement due then is not just an accounting formality; it is the essential foundation for securing the company's banking future and confirming its revenue guidance of up to €2.4 billion.